SLN124

DRUG4 trials

Sponsors

Silence Therapeutics PLC, Silence Therapeutics plc

Conditions

Healthy VolunteersLow Risk Myelodysplastic SyndromeNon-transfusion-dependent ThalassemiaPolycythemia VeraVery-Low Risk Myelodysplastic Syndrome

Early Phase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

CompletedNCT04559971

Silence Therapeutics plcHealthy Volunteers

Start: 2020-09-03End: 2021-03-23Updated: 2023-04-21

Phase 1

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

CompletedNCT04718844

Silence Therapeutics plcLow Risk Myelodysplastic Syndrome, Non-transfusion-dependent Thalassemia, Very-Low Risk Myelodysplastic Syndrome

Start: 2021-04-14End: 2023-05-23Updated: 2024-01-03

Study to Assess SLN124 in Patients With Polycythemia Vera

Active, not recruitingNCT05499013

Silence Therapeutics plcPolycythemia Vera

Start: 2023-01-26End: 2030-03-31Updated: 2025-12-19

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera

Active, not recruitingCTIS2023-503544-13-00

Silence Therapeutics PLCPolycythemia Vera

Start: 2023-11-02Target: 58Updated: 2025-10-28

Related Papers

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

Blood2024-11-054 citations

SLN124, a GalNAc Conjugated 19-Mer Double-Stranded SiRNA Reduces Iron and Increases Hepcidin Levels of Healthy Volunteers in a Phase 1 Clinical Study

Blood2021-11-054 citations